BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33099028)

  • 21. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
    Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
    Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.
    Hagström H; Nasr P; Ekstedt M; Stål P; Hultcrantz R; Kechagias S
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1148-1156.e4. PubMed ID: 30471458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy.
    Mikolasevic I; Domislovic V; Krznaric-Zrnic I; Krznaric Z; Virovic-Jukic L; Stojsavljevic S; Grgurevic I; Milic S; Vukoja I; Puz P; Aralica M; Hauser G
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208576
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort.
    Yoo HW; Jin HY; Yon DK; Effenberger M; Shin YH; Kim SY; Yang JM; Kim MS; Koyanagi A; Jacob L; Smith L; Yoo IK; Shin JI; Lee SW
    J Korean Med Sci; 2021 Oct; 36(41):e291. PubMed ID: 34697932
    [TBL] [Abstract][Full Text] [Related]  

  • 26.  Most overweight and obese Indian children have nonalcoholic fatty liver disease.
    Pawar SV; Zanwar VG; Choksey AS; Mohite AR; Jain SS; Surude RG; Contractor QQ; Rathi PM; Verma RU; Varthakavi PK
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):853-861. PubMed ID: 27740518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study.
    Abeysekera KWM; Fernandes GS; Hammerton G; Portal AJ; Gordon FH; Heron J; Hickman M
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):295-305. PubMed ID: 31954687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
    Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C.
    Pokorska-Śpiewak M; Kowalik-Mikołajewska B; Aniszewska M; Pluta M; Marczyńska M
    BMC Infect Dis; 2017 May; 17(1):361. PubMed ID: 28535787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria.
    Sánchez-Torrijos Y; Ampuero J; Pérez Palacios D; Gallego-Durán R; Romero-Gómez M
    Rev Esp Enferm Dig; 2019 Apr; 111(4):270-274. PubMed ID: 30810332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between telomere length and hepatic fibrosis in non-alcoholic fatty liver disease.
    Shin HK; Park JH; Yu JH; Jin YJ; Suh YJ; Lee JW; Kim W;
    Sci Rep; 2021 Sep; 11(1):18004. PubMed ID: 34504179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease.
    Marella HK; Reddy YK; Jiang Y; Ganguli S; Podila PSB; Snell PD; Kovalic AJ; Cholankeril G; Singal AK; Nair S; Maliakkal B; Satapathy SK
    Clin Transl Gastroenterol; 2020 Apr; 11(4):e00165. PubMed ID: 32352687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis.
    Jung CH; Rhee EJ; Kwon H; Chang Y; Ryu S; Lee WY
    Endocrinol Metab (Seoul); 2020 Mar; 35(1):165-176. PubMed ID: 32207277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
    Kim D; Kim WR; Kim HJ; Therneau TM
    Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.
    Singh A; Le P; Lopez R; Alkhouri N
    Hepatol Int; 2018 Jan; 12(1):37-43. PubMed ID: 29318450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do serum markers of liver fibrosis vary by HCV infection in patients with alcohol use disorder?
    Sanvisens A; Muñoz A; Bolao F; Zuluaga P; Farré M; Jarrin I; Tor J; Muga R
    Drug Alcohol Depend; 2018 Jul; 188():180-186. PubMed ID: 29778771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients.
    Ponziani FR; Del Zompo F; Nesci A; Santopaolo F; Ianiro G; Pompili M; Gasbarrini A;
    Aliment Pharmacol Ther; 2020 Sep; 52(6):1060-1068. PubMed ID: 32628793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
    Ito T; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Nishimura D; Toyoda H; Kumada T; Goto H; Hirooka Y
    J Gastroenterol Hepatol; 2019 Jan; 34(1):207-214. PubMed ID: 30144360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.
    Yanavich C; Pacheco AG; Cardoso SW; Nunes EP; Chaves U; Freitas G; Santos R; Morata M; Veloso VG; Grinsztejn B; Perazzo H
    HIV Med; 2021 Jul; 22(6):445-456. PubMed ID: 33529485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.